A major UK bioscience investor needed due diligence on a cell biology reagents investment opportunity.


We conducted IP and commercial due diligence, reviewing the target company’s patent estate and conducting selective IP searches, which revealed a weaker IP position than first thought. We identified the market segments for the technology, ranking them by commercial attractiveness and unmet need.

Following interviews with key players in each priority market segment, it emerged that the market potential was smaller than originally thought, the rate of market penetration would be slower and the benefit of the target technology would be considered incremental rather than a step change.

Explore Our Due Diligence Services

Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate. 

Related Case Studies